International Journal of Oral Biology

The Korean Academy of Oral Biology (대한구강생물학회)
권호 표지
DOI QR코드

DOI QR Code

Discovery and characterization of berberine derivatives as stimulators of osteoblast differentiation

  • Han, Younho (Department of Oral Pharmacology, Wonkwang University College of Dentistry) ;
  • Park, Won-Jong (Department of Oral Pharmacology, Wonkwang University College of Dentistry)
  • Received : 2019.12.02
  • Accepted : 2019.12.16
  • Published : 2019.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Berberine has been used clinically for more than a decade to treat various diseases, has been shown to be effective in osteoblast differentiation, and is a potential treatment option for osteoporosis. However, compared with existing osteoporosis drugs, berberine is somewhat less effective. This study aimed to identify a new compound with efficacy superior to that of berberine. The osteogenic activities of various berberine derivatives were evaluated via cell differentiation in C2C12 preosteoblast cell lines. Alkaline phosphatase (ALP) staining assay and structure-activity relationship demonstrated that compound 2b had a potent osteogenic effect. Furthermore, compound 2b dose dependently increased ALP activity and showed no toxicity at the effective concentration, indicating its efficacy. Additionally, compound 2b upregulated BMP2-induced transcriptional activity in a promoter activity assay using ALP, BSP, and OC promoters.

Keywords

References

  1. Snyman L. Menopause-related osteoporosis. South Afr Fam Pract 2014;56:174-7. doi: 10.1080/20786204.2014.932549.
  2. Ensrud KE, Crandall CJ. Osteoporosis. Ann Intern Med 2017;167:ITC17-32. doi: 10.7326/AITC201708010.
  3. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938-56. doi: 10.1016/j.joms.2014.04.031.
  4. Kraenzlin ME, Meier C. Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol 2011;7:647-56. doi: 10.1038/nrendo.2011.108.
  5. Endo I, Mastumoto T. [Bone and Stem Cells. Regulatory mechanism of mesenchymal stem cell differentiation to osteoblasts]. Clin Calcium 2014;24:555-64. Japanese. doi:CliCa1404555564.
  6. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature 2003;423:349-55. doi: 10.1038/nature01660.
  7. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003;4:638-49. doi:10.1038/nrg1122.
  8. Jensen ED, Gopalakrishnan R, Westendorf JJ. Regulation of gene expression in osteoblasts. Biofactors 2010;36:25-32. doi: 10.1002/biof.72.
  9. Li Y, Ge C, Long JP, Begun DL, Rodriguez JA, Goldstein SA, Franceschi RT. Biomechanical stimulation of osteoblast gene expression requires phosphorylation of the RUNX2 transcription factor. J Bone Miner Res 2012;27:1263-74. doi:10.1002/jbmr.1574.
  10. Chen D, Harris MA, Rossini G, Dunstan CR, Dallas SL, Feng JQ, Mundy GR, Harris SE. Bone morphogenetic protein 2 (BMP-2) enhances BMP-3, BMP-4, and bone cell differentiation marker gene expression during the induction of mineralized bone matrix formation in cultures of fetal rat calvarial osteoblasts. Calcif Tissue Int 1997;60:283-90. doi: 10.1007/s002239900230.
  11. Long F. Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol 2011;13:27-38. doi:10.1038/nrm3254.
  12. Chen J, Shapiro HS, Sodek J. Development expression of bone sialoprotein mRNA in rat mineralized connective tissues. J Bone Miner Res 1992;7:987-97. doi: 10.1002/jbmr.5650070816.
  13. Jin Y, Khadka DB, Cho WJ. Pharmacological effects of berberine and its derivatives: a patent update. Expert Opin Ther Pat 2016;26:229-43. doi: 10.1517/13543776.2016.1118060.
  14. Wei P, Jiao L, Qin LP, Yan F, Han T, Zhang QY. Effects of berberine on differentiation and bone resorption of osteoclasts derived from rat bone marrow cells. Zhong Xi Yi Jie He Xue Bao 2009;7:342-8. doi: 10.3736/jcim20090408.
  15. Li H, Miyahara T, Tezuka Y, Tran QL, Seto H, Kadota S. Effect of berberine on bone mineral density in SAMP6 as a senile osteoporosis model. Biol Pharm Bull 2003;26:110-1. doi:10.1248/bpb.26.110.
  16. Han SY, Kim YK. Berberine suppresses RANKL-induced osteoclast differentiation by inhibiting c-Fos and NFATc1 expression. Am J Chin Med 2019;47:439-55. doi: 10.1142/S0192415X19500228.
  17. Lee HW, Suh JH, Kim HN, Kim AY, Park SY, Shin CS, Choi JY, Kim JB. Berberine promotes osteoblast differentiation by Runx2 activation with p38 MAPK. J Bone Miner Res 2008;23: 1227-37. doi: 10.1359/jbmr.080325.
  18. Jin Y, Han Y, Khadka DB, Zhao C, Lee KY, Cho WJ. Discovery of isoquinolinoquinazolinones as a novel class of potent PPAR${\gamma}$ antagonists with anti-adipogenic effects. Sci Rep 2016;6:34661. doi: 10.1038/srep34661.
  19. Bakour SH, Williamson J. Latest evidence on using hormone replacement therapy in the menopause. Obstet Gynaecol 2015;17:20-8. doi: 10.1111/tog.12155.
  20. Bowring CE, Francis RM. National Osteoporosis Society's Position statement on hormone replacement therapy in the prevention and treatment of osteoporosis. Menopause Int 2011;17:63-5. doi: 10.1258/mi.2011.011012.
  21. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45. doi: 10.1001/jama.282.7.637.
  22. Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, Vogel V, Shepherd J, Vachon C, Smith-Bindman R, Kerlikowske K. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst 2009;101:384-98. doi: 10.1093/jnci/djp018.
  23. Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, Motala A, Shekelle PG. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 2014;161:711-23. doi:10.7326/M14-0317.
  24. Solomon CG. Postmenopausal osteoporosis. N Engl J Med 2016;374:1797. doi: 10.1056/NEJMx160008.
  25. Kharazmi M, Hallberg P, Michaelsson K. Gender related difference in the risk of bisphosphonate associated atypical femoral fracture and osteonecrosis of the jaw. Ann Rheum Dis 2014;73:1594. doi: 10.1136/annrheumdis-2013-205080.
  26. Eekman DA, Bultink IE, Heijboer AC, Dijkmans BA, Lems WF. Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice. BMC Musculoskelet Disord 2011;12:167. doi: 10.1186/1471-2474-12-167.
  27. Lewiecki EM. New and emerging concepts in the use of denosumab for the treatment of osteoporosis. Ther Adv Musculoskelet Dis 2018;10:209-23. doi: 10.1177/1759720X18805759.
  28. Hu JP, Nishishita K, Sakai E, Yoshida H, Kato Y, Tsukuba T, Okamoto K. Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways. Eur J Pharmacol 2008;580:70-9. doi:10.1016/j.ejphar.2007.11.013.
  29. Zhou L, Song F, Liu Q, Yang M, Zhao J, Tan R, Xu J, Zhang G, Quinn JM, Tickner J, Xu J. Berberine sulfate attenuates osteoclast differentiation through RANKL induced NF-${\kappa}B$ and NFAT pathways. Int J Mol Sci 2015;16:27087-96. doi:10.3390/ijms161125998.
  30. Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, Rosen V, Wozney JM, Fujisawa-Sehara A, Suda T. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 1994;127(6 Pt 1):1755-66. doi: 10.1083/jcb.127.6.1755.
  31. Han Y, Jin Y, Lee SH, Khadka DB, Cho WJ, Lee KY. Berberine bioisostere Q8 compound stimulates osteoblast differentiation and function in vitro. Pharmacol Res 2017;119:463-75. doi:10.1016/j.phrs.2017.03.002.
  32. Berendsen AD, Olsen BR. Osteoblast-adipocyte lineage plasticity in tissue development, maintenance and pathology. Cell Mol Life Sci 2014;71:493-7. doi: 10.1007/s00018-013-1440-z.
  33. Chen JR, Lazarenko OP, Zhang J, Blackburn ML, Ronis MJ, Badger TM. Diet-derived phenolic acids regulate osteoblast and adipocyte lineage commitment and differentiation in young mice. J Bone Miner Res 2014;29:1043-53. doi:10.1002/jbmr.2034.
  34. Arumugam B, Vairamani M, Partridge NC, Selvamurugan N. Characterization of Runx2 phosphorylation sites required for TGF-${\beta}$1-mediated stimulation of matrix metalloproteinase-13 expression in osteoblastic cells. J Cell Physiol 2018;233:1082-94. doi: 10.1002/jcp.25964.
  35. Vimalraj S, Arumugam B, Miranda PJ, Selvamurugan N. Runx2: structure, function, and phosphorylation in osteoblast differentiation. Int J Biol Macromol 2015;78:202-8. doi:10.1016/j.ijbiomac.2015.04.008.
  36. Ogasawara T, Kawaguchi H, Jinno S, Hoshi K, Itaka K, Takato T, Nakamura K, Okayama H. Bone morphogenetic protein 2-induced osteoblast differentiation requires Smad-mediated down-regulation of Cdk6. Mol Cell Biol 2004;24:6560-8. doi:10.1128/MCB.24.15.6560-6568.2004.